Genmab
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Genmab and other ETFs, options, and stocks.About GMAB
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia.
CEOJan G. J. van de Winkel, PhD
CEOJan G. J. van de Winkel, PhD
Employees2,682
Employees2,682
HeadquartersCopenhagen, Central Denmark
HeadquartersCopenhagen, Central Denmark
Founded1998
Founded1998
Employees2,682
Employees2,682
GMAB Key Statistics
Market cap19.92B
Market cap19.92B
Price-Earnings ratio13.63
Price-Earnings ratio13.63
Dividend yield—
Dividend yield—
Average volume1.42M
Average volume1.42M
High today$32.48
High today$32.48
Low today$31.39
Low today$31.39
Open price$31.68
Open price$31.68
Volume2.35M
Volume2.35M
52 Week high$33.65
52 Week high$33.65
52 Week low$17.24
52 Week low$17.24
Stock Snapshot
As of today, Genmab(GMAB) shares are valued at $32.44. The company's market cap stands at 19.92B, with a P/E ratio of 13.63.
On 2025-11-30, Genmab(GMAB) stock moved within a range of $31.39 to $32.48. With shares now at $32.44, the stock is trading +3.3% above its intraday low and -0.1% below the session's peak.
Trading activity shows a volume of 2.35M, compared to an average daily volume of 1.42M.
The stock's 52-week range extends from a low of $17.24 to a high of $33.65.
The stock's 52-week range extends from a low of $17.24 to a high of $33.65.
Analyst ratings
65%
of 26 ratingsBuy
65.4%
Hold
30.8%
Sell
3.8%